MDxHealth SA (MDXH) Q3 2026 Earnings Call Transcript

Impact · against what's priced in

MDxHealth shares are likely to face downward pressure following a Q3 miss driven by sales force instability and the discontinuation of the Resolve product. These operational disruptions create a likely lag in revenue recovery, undermining near-term earnings estimates.

MDXH−0.50

No priced-in read yet

In context

The company missed Q3 expectations due to commercial execution disruptions and accelerated turnover in the sales organization following the discontinuation of Resolve.

Read from the article alone

• transcript
• earnings
• healthcare
• MDXH
• commercial execution
• diagnostics
• sales turnover

Search tags